Ernexa Therapeutics Inc.
ERNA
$6.80
-$0.59-7.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.00K | 488.00K | 535.00K | 582.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.00K | 488.00K | 535.00K | 582.00K |
| Cost of Revenue | -- | 0.00 | -60.00K | 35.00K | 96.00K |
| Gross Profit | -- | 1.00K | 548.00K | 500.00K | 486.00K |
| SG&A Expenses | 5.16M | 5.28M | 7.71M | 10.24M | 13.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.32M | 9.92M | 12.25M | 14.73M | 17.83M |
| Operating Income | -9.32M | -9.92M | -11.76M | -14.19M | -17.25M |
| Income Before Tax | -14.13M | -18.31M | -43.67M | -46.06M | -44.51M |
| Income Tax Expenses | -45.00K | 28.00K | 34.00K | 34.00K | 30.00K |
| Earnings from Continuing Operations | -14.08 | -18.34 | -43.70 | -46.09 | -44.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.08M | -18.34M | -43.70M | -46.09M | -44.54M |
| EBIT | -9.32M | -9.92M | -11.76M | -14.19M | -17.25M |
| EBITDA | -9.25M | -9.85M | -11.67M | -14.08M | -17.11M |
| EPS Basic | -81.17 | -132.98 | -1.97K | -2.34K | -2.74K |
| Normalized Basic EPS | -52.21 | -90.53 | -334.71 | -567.29 | -819.08 |
| EPS Diluted | -81.17 | -132.98 | -1.97K | -2.34K | -2.74K |
| Normalized Diluted EPS | -52.21 | -90.53 | -334.71 | -567.29 | -819.08 |
| Average Basic Shares Outstanding | 1.01M | 780.80K | 466.20K | 273.40K | 145.50K |
| Average Diluted Shares Outstanding | 1.01M | 780.80K | 466.20K | 273.40K | 145.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.00% | -0.02% | -0.02% |